Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
Istituto Oncologico Veneto IRCCS
Istituto Oncologico Veneto IRCCS
Aulos Bioscience, Inc.
Sotio Biotech Inc.
AstraZeneca
Mayo Clinic
Neonc Technologies, Inc.
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Mayo Clinic
University of Pittsburgh
Sotio Biotech Inc.
Incyte Corporation
Memgen, Inc.
Pfizer
Sensei Biotherapeutics, Inc.
Incyte Corporation
University of Virginia
Incyte Corporation
University of Pittsburgh
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
UNICANCER
Vincerx Pharma, Inc.
Arcus Biosciences, Inc.
University of Florida
Massachusetts General Hospital
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Nektar Therapeutics
Jules Bordet Institute
Incyte Corporation
Genocea Biosciences, Inc.
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Incyte Corporation
MultiVir, Inc.
Vanderbilt-Ingram Cancer Center
Emory University